Results: Salmeterol and fluticasone propionate powder marked improvement in asthma symptoms.
结果：沙美特罗替卡松粉剂明显改善哮喘病状。
Objective To evaluate the clinical effect of inhaling salmeterol-fluticasone on patients with COPD.
目的探讨吸入沙美特罗-替卡松粉治疗慢性阻塞性肺疾病（COPD）的疗效。
Conclusion Salmeterol and fluticasone propionate inhalant can improve pulmonary function in COPD patients.
结论沙美特罗替卡松干粉吸入能够改善慢性阻塞性肺疾病的肺功能。
Conclusion: The onset time and level of asthma can be decreased with proper dosage and inhalation method of Salmeterol fluticasone propionate.
结论：沙美特罗替卡松治疗哮喘，只要用量恰当，吸入的方法正确，可以减少哮喘发作的次数和减轻哮喘发作的程度。
Compared with regular salbutamol, regular salmeterol was not associated with a significant increase in fatal or nonfatal serious adverse events in patients not taking inhaled corticosteroids.
对不吸入糖皮质激素的患者来说，规律使用沙美特罗与规律使用沙丁胺醇相比，其致死性及非致死性严重不良事件的发生率并无显著增加。
Clinical implications of this review are that for patients with asthma that is poorly controlled with moderate doses of inhaled corticosteroids, additional salmeterol can give symptomatic benefit.
该综述与临床的联系在于：对于使用中等剂量吸入激素控制效果欠佳的哮喘患者，加用沙美特罗有助于症状的改善。
Clinical implications of this review are that for patients with asthma that is poorly controlled with moderate doses of inhaled corticosteroids, additional salmeterol can give symptomatic benefit.
该综述与临床的联系在于：对于使用中等剂量吸入激素控制效果欠佳的哮喘患者，加用沙美特罗有助于症状的改善。
应用推荐